Cabotegravir and Rilpivirine: A Long-Acting Injectable Antiretroviral Treatment for Human Immunodeficiency Virus

There have been significant developments in effective human immunodeficiency virus treatment since the first antiretroviral was approved. A significant number of people living with human immunodeficiency virus have not been able to maintain viral suppression on oral therapy. A long-acting monthly injectable antiretroviral regimen consisting of cabotegravir and rilpivirine has been approved for individuals who are virally suppressed. This regimen is a good option for those who struggle with adherence on a daily oral regimen or prefer a long-acting regimen.

Source: The Journal for Nurse Practitioners - December 21, 2021 Category: Nursing Authors: Adam Leonard, Janessa Broussard, Natalie Wilson, Carol Dawson-Rose Tags: Featured Article Source Type: research